Cargando…
SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AIMS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834075/ https://www.ncbi.nlm.nih.gov/pubmed/36694588 http://dx.doi.org/10.3934/microbiol.2022029 |
_version_ | 1784868380674621440 |
---|---|
author | Fiorino, Sirio Carusi, Andrea Hong, Wandong Cernuschi, Paolo Gallo, Claudio Giuseppe Ferrara, Emanuele Maloberti, Thais Visani, Michela Lari, Federico de Biase, Dario Zippi, Maddalena |
author_facet | Fiorino, Sirio Carusi, Andrea Hong, Wandong Cernuschi, Paolo Gallo, Claudio Giuseppe Ferrara, Emanuele Maloberti, Thais Visani, Michela Lari, Federico de Biase, Dario Zippi, Maddalena |
author_sort | Fiorino, Sirio |
collection | PubMed |
description | In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This decrease is certainly associated with the introduction of vaccination measures. The process of the development of effective vaccines represents an important challenge. Overall, the breakthrough infections occurring in vaccinated subjects are in most cases less severe than those observed in unvaccinated individuals. This review examines the factors affecting the immunogenicity of vaccines against SARS-CoV-2 and the possible role of nutrients in modulating the response of distinct immune cells to the vaccination. |
format | Online Article Text |
id | pubmed-9834075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AIMS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98340752023-01-23 SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses Fiorino, Sirio Carusi, Andrea Hong, Wandong Cernuschi, Paolo Gallo, Claudio Giuseppe Ferrara, Emanuele Maloberti, Thais Visani, Michela Lari, Federico de Biase, Dario Zippi, Maddalena AIMS Microbiol Overview In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This decrease is certainly associated with the introduction of vaccination measures. The process of the development of effective vaccines represents an important challenge. Overall, the breakthrough infections occurring in vaccinated subjects are in most cases less severe than those observed in unvaccinated individuals. This review examines the factors affecting the immunogenicity of vaccines against SARS-CoV-2 and the possible role of nutrients in modulating the response of distinct immune cells to the vaccination. AIMS Press 2022-11-16 /pmc/articles/PMC9834075/ /pubmed/36694588 http://dx.doi.org/10.3934/microbiol.2022029 Text en © 2022 the Author(s), licensee AIMS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ) |
spellingShingle | Overview Fiorino, Sirio Carusi, Andrea Hong, Wandong Cernuschi, Paolo Gallo, Claudio Giuseppe Ferrara, Emanuele Maloberti, Thais Visani, Michela Lari, Federico de Biase, Dario Zippi, Maddalena SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses |
title | SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses |
title_full | SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses |
title_fullStr | SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses |
title_full_unstemmed | SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses |
title_short | SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses |
title_sort | sars-cov-2 vaccines: what we know, what we can do to improve them and what we could learn from other well-known viruses |
topic | Overview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834075/ https://www.ncbi.nlm.nih.gov/pubmed/36694588 http://dx.doi.org/10.3934/microbiol.2022029 |
work_keys_str_mv | AT fiorinosirio sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT carusiandrea sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT hongwandong sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT cernuschipaolo sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT galloclaudiogiuseppe sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT ferraraemanuele sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT malobertithais sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT visanimichela sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT larifederico sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT debiasedario sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses AT zippimaddalena sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses |